Akari Therapeutics enters merger deal with Peak Bio
2024-03-06
孤儿药免疫疗法快速通道临床3期临床2期
Preview
来源: Pharmaceutical Technology
Akari Therapeutics has signed a definitive agreement with Peak Bio to merge in an all-stock transaction, creating a diversified pipeline with assets across various development stages.
The merged entity will operate under the name Akari Therapeutics Plc.
Shareholders of both companies will hold approximately 50% equity in the new entity.
The combined pipeline will have an antibody-drug-conjugate (ADC) toolkit with payload and linker technologies.
See Also:PTC TherapeuticsPTC Therapeutics files patent for pharmaceutical composition for treating various diseases
Preview
来源: Pharmaceutical Technology
Sorrento Therapeutics files patent for stable oral liquid pharmaceutical composition of celecoxib for pain relief
Preview
来源: Pharmaceutical Technology
The combined business will merge chemotherapy with immunotherapy strategies for the development of new solutions for cancer.
Akari’s lead product, nomacopan, is a bispecific recombinant inhibitor of complement C5 and leukotriene B4.
This product is currently in a Phase III clinical trial for paediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.
The FDA previously granted orphan drug, fast track and rare paediatric disease designations to nomacopan for this patient population.
It also received orphan drug designation from the European Commission for the treatment of hematopoietic stem cell transplantation.
Another asset of Akari, PASylated-nomacopan, a long-acting type of nomacopan, is nearing the end of pre-clinical development, targeting geographic atrophy with the promise of extending the dosing interval and reducing the risk of choroidal neovascularisation.
Peak Bio will also contribute its PHP-303, a Phase II-ready programme for treating alpha-1 antitrypsin deficiencyalpha-1 antitrypsin deficiency, licensed from Bayer Healthcare.
The transaction will be completed in the second quarter of 2024, pending shareholder approval and other customary closing conditions. Post-merger, the company plans to prioritise its programmes, establish updated timelines and explore near-term value-creation opportunities.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。